Medical Affairs and Clinical Evidence Generation
Roche's primary commercial strategy in pharmaceuticals is the generation and dissemination of clinical evidence through medical affairs teams embedded in every major market. Publication of trial data in high-impact journals, presentation at oncology congresses (ASCO, ESMO, ASH), and direct medical education programmes for oncologists, haematologists, and neurologists constitute the primary demand generation mechanism in a prescription-only pharmaceutical market where physician prescribing decisions are driven by clinical evidence quality rather than consumer advertising.
Companion Diagnostics Co-Launch Strategy
Roche coordinates the simultaneous commercial launch of companion diagnostic tests alongside the approved therapeutic, ensuring that prescribing physicians have immediate access to the patient selection test at the point of regulatory approval. This co-launch strategy accelerates drug uptake by eliminating the diagnostic access barrier that delayed earlier precision medicine commercialisations, and it generates incremental diagnostics revenue that improves the return on the combined pharmaceutical-diagnostics development investment.